Кардиоваскулярная безопасность применения нестероидных противовоспалительных препаратов при хронических воспалительных ревматических заболеваниях
Кардиоваскулярная безопасность применения нестероидных противовоспалительных препаратов при хронических воспалительных ревматических заболеваниях
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Ревматические заболевания (РЗ), такие как ревматоидный артрит, системная красная волчанка, анкилозирующий спондилит, псориатический артрит, спондилоартриты, васкулиты, подагра, связаны с увеличением сердечно-сосудистой заболеваемости и смертности. Основными причинами повышения кардиоваскулярного риска являются воспалительные поражения сердца и сосудов, ускоренное прогрессирование атеросклероза на фоне хронического воспаления, а также побочные эффекты медикаментозной терапии. Нестероидные противовоспалительные препараты (НПВП) широко применяются в клинической практике и входят в список наиболее назначаемых лекарственных препаратов, их используют до 30 млн человек ежедневно. Известно, что НПВП обладают негативным влиянием на сердечно-сосудистую систему (ССС). Однако на фоне приема препаратов этой группы также снижается выраженность воспалительного процесса, являющегося независимым фактором риска осложнений со стороны ССС. Поэтому у больных РЗ теоретически возможно снижение выраженности кардиоваскулярных побочных эффектов при применении НПВП. В статье рассматриваются вопросы кардиоваскулярной безопасности НПВП, молекулярные механизмы, лежащие в основе негативного влияния лекарственных средств этой группы на ССС, критически оцениваются опубликованные в научной литературе результаты основных исследований, касающихся кардиоваскулярной безопасности НПВП на фоне хронического воспаления.
Ключевые слова: сердечно-сосудистые заболевания, кардиоваскулярный риск, ревматические заболевания, ревматоидный артрит, системная красная волчанка, псориатический артрит, анкилозирующий спондилит, хроническое воспаление, нестероидные противовоспалительные препараты.
Keywords: cardiovascular diseases, cardiovascular risk, rheumatic diseases, rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, ankylosing spondylitis, chronic inflammation, non-steroidal anti-inflammatory drugs.
Ключевые слова: сердечно-сосудистые заболевания, кардиоваскулярный риск, ревматические заболевания, ревматоидный артрит, системная красная волчанка, псориатический артрит, анкилозирующий спондилит, хроническое воспаление, нестероидные противовоспалительные препараты.
________________________________________________
Keywords: cardiovascular diseases, cardiovascular risk, rheumatic diseases, rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, ankylosing spondylitis, chronic inflammation, non-steroidal anti-inflammatory drugs.
Список литературы
1. Заводовский Б.В. Влияние нестероидных противовоспалительных препаратов на сердечно-сосудистую систему. Кардиология. 2015;55(7):84-88 [Zavodovskij BV. Effect of non-steroidal anti-inflammatory drugs on the cardiovascular system. Kardiologija. 2015;55(7):84-88 (In Russ.)]. doi: 10.18565/cardio.2015.7.84-88
2. Каратеев А.Е., Новикова Д.С., Насонов Е.Л. Новые данные, касающиеся безопасности нестероидных противовоспалительных препаратов: представление о «класс-специфическом» высоком кардиоваскулярном риске селективных ингибиторов циклооксигеназы 2 устарело. Научно-практическая ревматология. 2017;55(2):218-223 [Karateev AE, Novikova DS, Nasonov EL. New data on the safety of nonsteroidal anti-inflammatory drugs: the concept of the high class-specific cardiovascular risk of selective cyclooxygenase-2 inhibitors is outdated. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):218-223 (In Russ.)]. doi: 10.14412/ 1995-4484-2017-218-223
3. Peters M, Symmons D, Mccarey D, Dijkmans B, Nicola P, Kvien T, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-331.
doi: 10.1136/ard.2009.113696
4. Peters M, van Halm V, Voskuyl A, Smulders Y, Boers M, Lems W, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A Prospective Study. Arthritis Rheum. 2009;61:1571-1579. doi: 10.1002/art.24836
5. Nicola P, Maradit-Kremers H, Roger V, Jacobsen S, Crowson C, Ballman K, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52:412-420. doi: 10.1002/art.20855
6. Середавкина Н.В., Смирнов А.В., Дыдыкина И.С., Решетняк Т.М. Глюкокортикоиды в лечении системной красной волчанки: положительные и отрицательные стороны. Клиницист. 2014;(1):63-70 [Seredavkina NV, Smirnov AV, Dydykina IS, Reshetnyak TM. Glucocorticoids in the treatment of systemic lupus erythematosus: positive and negative sides. Klinicist. 2014;(1):63-70 (In Russ.)].
doi: 10.17650/1818-8338-2014-1-63-70
7. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337. PMID: 11665973
8. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77-95. doi: 10.1016/ j.semarthrit.2012.12.002
9. Насонов Е.Л., Мазуров В.И., Лила А.М., Эрдес Ш.Ф., Каратеев Д.Е., Верткин А.Л., Зырянов С.К., Дубиков А.И., Фролов М.Ю., Обухова О.В. Резолюция Совещания Экспертов по теме: «Вопросы повышения доступности инновационных методов для пациентов со спондилоартритами». Научно-практическая ревматология. 2017;55(4):457-460 [Nasonov EL, Mazurov VI, Lila AM, Erdes ShF, Karateev DE, Vertkin AL, Zyrjanov SK, Dubikov AI, Frolov MYu, Obuhova OV. Resolution of the Meeting of Experts on the topic: “Issues of increasing the availability of innovative methods for patients with spondylitis”. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):457-460 (In Russ.)].
doi: 10.14412/1995-4484-2017-457-459
10. Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63:550-556.
doi: 10.1002/acr.20408 PMID: 21452267
11. Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294-3304. doi: 10.1002/art.30581
12. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121:S9-S14. doi: 10.1016/j.amjmed.2008. 06.011
13. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010-2019. doi: 10.1002/art.10419
14. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562-2571. PMID: 10606363.
15. Павлова А.Б., Ахвердян Ю.Р., Симакова Е.С. и др. Определение адипонектина у работников промышленных предприятий с воспалительными заболеваниями суставов. Медицина труда и промышленная экология. 2013;(1):38-41 [Pavlova AB, Ahverdjan YuR, Simakova ES, et al. Determination of adiponectin in workers of industrial enterprises with inflammatory diseases of joints. Meditsina Truda i Promyshlennaya Ekologija. 2013;(1):38-41 (In Russ.)].
16. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013;12:1004-1015. doi: 10.1016/j.autrev.2013.03.013
17. Симакова Е.С., Заводовский Б.В., Сивордова Л.Е., Полякова Ю.В., Кравцов В.И., Зборовский А.Б. Прогностическое значение нарушений липидного обмена в патогенезе остеоартроза. Вестник Российской военно-медицинской академии. 2013;2(42):29-32 [Simakova ES, Zavodovskiy BV, Sivordova LE, Poljakova YuV, Kravcov VI, Zborovskiy AB. Prognostic value of violations of lipid metabolism in the pathogenesis of osteoarthritis. Vestnik Rossijskoj Voenno-Medicinskoj Akademii. 2013;2(42):29-32 (In Russ.)].
18. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.
doi: 10.1038/nature10146
19. Stevens R, Douglas K, Saratzis A, Kitas G. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2005;7:1-24. doi: 10.1017/S1462399405009154
20. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51:v3-11. doi: 10.1093/rheumatology/kes113
21. Liao K, Solomon D. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:45-52. doi: 10.3899/jrheum.090188
22. Mavrogeni S, Spargias K, Markussis V, Kolovou G, Demerouti E, Papadopoulou E, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm Allergy Drug Targets. 2009;8:390-397. PMID: 20025587.
23. Sandoo A, Kitas G, Carroll D, Veldhuijzen Van Zanten J. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res Ther. 2012;14:R117. doi: 10.1186/ar3847
24. Драпкина О.М., Ашихмин Я.И. Воздействие нестероидных противовоспалительных средств и селективных ингибиторов циклооксигеназы-2 на сердечно-сосудистую систему. Российские медицинские вести. 2007;12(3):62-66 [Drapkina OM, Ashikhmin YaI. Effect of nonsteroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors on cardio-vascular system. Rossijskie Medicinskie Vesti. 2007;12(3):62-66 (In Russ.)].
25. Сивордова Л.Е., Заводовский Б.В., Полякова Ю.В., Ахвердян Ю.Р. Доказательства целесообразности применения эторикоксиба в терапии остеоартроза у пациентов старших возрастных групп. Успехи геронтологии. 2016;29(2):286-290 [Sivordova LE, Zavodovskij BV, Poljakova YuV, Ahverdyan YuR. Evidence of the feasibility of using etorikoksib in the therapy of osteoarthritis in patients of older age groups. Uspekhi Gerontologii = Advanced Gerontology. 2016;29(2):286-290 (In Russ.)].
26. Насонов Е.Л., Насонова В.А., редакторы. Ревматология: национальное руководство. Москва: ГЭОТАР-Медиа; 2008. 720 с. [Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional’noe rukovodstvo [Rheumatology: National Guidelance]. Moscow: GEOTAR-Media; 2008. 720 p. (In Russ.)].
27. Заводовский Б.В., Сивордова Л.Е., Полякова Ю.В., Ахвердян Ю.Р., Кузнецова М.И., Зборовская И.А. Сравнительная эффективность и безопасность эторикоксиба и мелоксикама в лечении больных гонартрозом. Терапевтический архив. 2016;88:78-81 [Zavodovskij BV, Sivordova LE, Poljakova YuV, Ahverdjan YuR, Kuznecova MI, Zborovskaja IA. Comparative efficacy and safety of etorikoksib and meloxicam in the treatment of patients with gonarthrosis. Terapevticheskij Arhiv. 2016;88:78-81 (In Russ.)]. doi: 10.17116/terarkh 2016881278-81
28. Насонов Е.Л., Ивашкин В.Т., Яхно Н.Н., Мартынов А.И., Арутю-
нов Г.П., Каратеев А.Е., Алексеева Л.И., Чичасова Н.В., Евсеев М.А., Кукушкин М.Л., Лила А.М., Ребров А.П. и др. Проект Национальных клинических рекомендаций (Основные положения) Ассоциации ревматологов России, Российской гастроэнтерологической Ассоциации, Российского общества по изучению боли «Рациональное использование нестероидных противовоспалительных препаратов». Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):69-75 [Nasonov EL, Ivashkin VT, Jahno NN, Martynov AI, Arutjunov GP, Karateev AE, Alekseeva LI, Chichasova NV, Evseev MA, Kukushkin ML, Lila AM, Rebrov AP, et al. Project of National Clinical Recommendations (Basic Provisions) of the Association of Rheumatologists of Russia, the Russian Gastroenterological Association, the Russian Society for the Study of Pain “Rational Use of Non-steroidal Anti-Inflammatory Drugs”. Rossijskij Zhurnal Gastrojenterologii, Gepatologii, Koloproktologii. 2017;27(5):69-75 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-5-69-75
29. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857
30. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Argas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl
J Med. 2000;343(21):1520-1528. doi: 10.1056/NEJM 200011233 432103
31. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxiband valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081-1091. doi: 10.1056/NEJMoa050330
32. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080. doi: 10.1056/NEJMoa050405
33. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102. doi: 10.1056/NEJMoa050493
34. Back M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012;33:1928-1933. doi: 10.1093/eurheartj/ ehr421
35. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
doi: 10.1136/bmj.332.7553.1302
36. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL programme: a randomized comparison.
Lancet. 2006;368(9549):1771-1781. doi: 10.1016/S0140-6736(06) 69666-9
37. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1(7):e33. doi: 10.1371/journal.pctr.0010033
38. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. doi: 10.1016/S0140-6736(13)60900-9
39. Hirayama A, Tanahashi N, Daida H, Ishiguro N, Chachin M, Siguoka T. Assessing the Cardiovascular Risk Between Celecoxib and Nonselective Nonsteroidal Antiinflammatory Drugs in Patients With Rheumatoid Arthritis and Osteoarthritis. Circ J. 2014;78(1):194-205.
doi: 10.1253/circj.CJ-12-1573
40. Rahme E, Watson DJ, Kong SX, Toubouti Y, Le Lorier J. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2007;16(5):493-503.
doi: 10.1002/pds.1339
41. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, Torp-Pedersen C, Gislason GH. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235.
doi: 10.1161/CIRCULATIONAHA.110.004671
42. Sudano I, Flammer AJ, Roas S, Enseleit F, Noll G, Ruschitzka F. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep. 2012;14(4):304-309. doi: 10.1007/s11906-012-0274-7
43. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009;104(6):840-845. doi: 10.1016/ j.amjcard.2009.05.014
44. Dallob A, Hawkey CJ, Greenberg HM, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. J Clin Pharmacol. 2003;43(6):573-585. doi: 10.1177/ 0091270003253703
45. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA. 2012;109(43):17597-17602. doi: 10.1073/pnas. 1209192109
46. St Germaine CG, Bogaty P, Boyer L, Hanley J, Engert JC, Brophy JM. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. Am J Cardiol. 2010;105(12):1740-1745.
doi: 10.1016/j.amjcard.2010.01.352
47. Shapiro MS. An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated Puzzle? Mol Pharmacol. 2009;76:942-945. doi: 10.1124/ mol.109.059683
48. Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42:27-38.
doi: 10.1111/jcpt.12484
49. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DPM, Nurmohamed MT. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016;0:1-12. doi: 10.1136/annrheumdis-2016-209775
50. Horbach SJ, Lopes RD, da C Guaragna JC, Martini F, Mehta RH, Petracco JB, Bodanese LC, Filho AC, Cirenza C, de Paola AA. NAFARM Investigators. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med. 2011;124(11):1036-1042. doi: 10.1016/j.amjmed.2011.07.026
51. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68(3):367-372. doi: 10.1136/ ard.2007.076760
52. Lindhardsen J, Gislason GH, Jacobsen S, Ahlehoff O, Olsen AMS, Madsen OR, Torp-Pedersen C, Hansen PR. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;73(8):1515-1521. doi: 10.1136/annrheumdis-2012-203137
53. De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol. 2014;62(6):437-448. PubMed ID 25029569. http://www.minervamedica.it/en/journals/minerva-cardioangiologica/article.php?cod=R05 Y9999N00A 140053
54. MacDonald Т, Hawkey С, Ford I, et al. On behalf of SCOT investigators (The Standard Care versus Celecoxib Outcome Trial). BMJ Open. 2013;3:e002295. https://clinicaltrials.gov/ct2/show/NCT00447759
55. Nissen SE, Yeomans ND, Solomon DH, Luscher TF, et al. for the PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New Engl J Med. 2016.
doi: 10.1056/NEJMoa1611593
56. Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewé R, van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3:e000397. doi: 10.1136/rmdopen-2016-000397
57. Tsai W-C, Ou T-T, Yen J-H, Wu C-C, Tung Y-C. Long-Term Frequent Use of Non-Steroidal Anti-Inflammatory Drugs Might Protect Patients with Ankylosing Spondylitis from Cardiovascular Diseases: A Nationwide Case-Control Study. PLoS ONE. 2015;10(5):e0126347.
doi: 10.1371/journal.pone.0126347
58. Ogdie A, Yu Y, Haynes K, Love TJ, et al. Risk of Major Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A population-based cohort study. Ann Rheum Dis. 2015 Feb;74(2):326-332. doi: 10.1136/annrheumdis-2014-205675
59. Kristensen LE, Jakobsen AK, Askling J, et al. Safety of etoricoxib, celecoxib, and nonselective nonsteroidal antiinflammatory drugs in ankylosing spondylitis and other spondyloarthritis patients: a Swedish National Population-based Cohort Study. Arthritis Care Res (Hoboken). 2015;67:1137-1149. doi: 10.1002 / acr.22555
60. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
61. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-489. doi: 10.1136/annrheumdis-2014-206624
62. Essers I, Stolwijk C, Boonen A, De Bruin ML, Bazelier MT, de Vries F, van Tubergen A. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis. 2016;75:203-209. doi: 10.1136 / annrheumdis-2014-206147
63. Zhang YP, Gong Y, Zeng QY, Hou ZD, Xiao ZY. A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. BMJ Open. 2015;5:e006957. doi: 10.1136/bmjopen-2014-006957
64. Tzu-Chieh Lin, Pharm B, Solomon DH, Tedeschi SK, Yoshida K, Yea-Huei Kao Yang. Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis. Am Heart Assoc. 2017;6:006874.
doi: 10.1161/JAHA.117.006874
2. Karateev AE, Novikova DS, Nasonov EL. New data on the safety of nonsteroidal anti-inflammatory drugs: the concept of the high class-specific cardiovascular risk of selective cyclooxygenase-2 inhibitors is outdated. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):218-223 (In Russ.)]. doi: 10.14412/ 1995-4484-2017-218-223
3. Peters M, Symmons D, Mccarey D, Dijkmans B, Nicola P, Kvien T, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-331.
doi: 10.1136/ard.2009.113696
4. Peters M, van Halm V, Voskuyl A, Smulders Y, Boers M, Lems W, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A Prospective Study. Arthritis Rheum. 2009;61:1571-1579. doi: 10.1002/art.24836
5. Nicola P, Maradit-Kremers H, Roger V, Jacobsen S, Crowson C, Ballman K, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52:412-420. doi: 10.1002/art.20855
6. [Seredavkina NV, Smirnov AV, Dydykina IS, Reshetnyak TM. Glucocorticoids in the treatment of systemic lupus erythematosus: positive and negative sides. Klinicist. 2014;(1):63-70 (In Russ.)].
doi: 10.17650/1818-8338-2014-1-63-70
7. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337. PMID: 11665973
8. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77-95. doi: 10.1016/ j.semarthrit.2012.12.002
9. [Nasonov EL, Mazurov VI, Lila AM, Erdes ShF, Karateev DE, Vertkin AL, Zyrjanov SK, Dubikov AI, Frolov MYu, Obuhova OV. Resolution of the Meeting of Experts on the topic: “Issues of increasing the availability of innovative methods for patients with spondylitis”. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):457-460 (In Russ.)].
doi: 10.14412/1995-4484-2017-457-459
10. Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63:550-556.
doi: 10.1002/acr.20408 PMID: 21452267
11. Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294-3304. doi: 10.1002/art.30581
12. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121:S9-S14. doi: 10.1016/j.amjmed.2008. 06.011
13. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010-2019. doi: 10.1002/art.10419
14. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562-2571. PMID: 10606363.
15. [Pavlova AB, Ahverdjan YuR, Simakova ES, et al. Determination of adiponectin in workers of industrial enterprises with inflammatory diseases of joints. Meditsina Truda i Promyshlennaya Ekologija. 2013;(1):38-41 (In Russ.)].
16. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013;12:1004-1015. doi: 10.1016/j.autrev.2013.03.013
17. [Simakova ES, Zavodovskiy BV, Sivordova LE, Poljakova YuV, Kravcov VI, Zborovskiy AB. Prognostic value of violations of lipid metabolism in the pathogenesis of osteoarthritis. Vestnik Rossijskoj Voenno-Medicinskoj Akademii. 2013;2(42):29-32 (In Russ.)].
18. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.
doi: 10.1038/nature10146
19. Stevens R, Douglas K, Saratzis A, Kitas G. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2005;7:1-24. doi: 10.1017/S1462399405009154
20. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51:v3-11. doi: 10.1093/rheumatology/kes113
21. Liao K, Solomon D. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:45-52. doi: 10.3899/jrheum.090188
22. Mavrogeni S, Spargias K, Markussis V, Kolovou G, Demerouti E, Papadopoulou E, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm Allergy Drug Targets. 2009;8:390-397. PMID: 20025587.
23. Sandoo A, Kitas G, Carroll D, Veldhuijzen Van Zanten J. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res Ther. 2012;14:R117. doi: 10.1186/ar3847
24. [Drapkina OM, Ashikhmin YaI. Effect of nonsteroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors on cardio-vascular system. Rossijskie Medicinskie Vesti. 2007;12(3):62-66 (In Russ.)].
25. [Sivordova LE, Zavodovskij BV, Poljakova YuV, Ahverdyan YuR. Evidence of the feasibility of using etorikoksib in the therapy of osteoarthritis in patients of older age groups. Uspekhi Gerontologii = Advanced Gerontology. 2016;29(2):286-290 (In Russ.)].
26. [Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional’noe rukovodstvo [Rheumatology: National Guidelance]. Moscow: GEOTAR-Media; 2008. 720 p. (In Russ.)].
27. [Zavodovskij BV, Sivordova LE, Poljakova YuV, Ahverdjan YuR, Kuznecova MI, Zborovskaja IA. Comparative efficacy and safety of etorikoksib and meloxicam in the treatment of patients with gonarthrosis. Terapevticheskij Arhiv. 2016;88:78-81 (In Russ.)]. doi: 10.17116/terarkh 2016881278-81
28. [Nasonov EL, Ivashkin VT, Jahno NN, Martynov AI, Arutjunov GP, Karateev AE, Alekseeva LI, Chichasova NV, Evseev MA, Kukushkin ML, Lila AM, Rebrov AP, et al. Project of National Clinical Recommendations (Basic Provisions) of the Association of Rheumatologists of Russia, the Russian Gastroenterological Association, the Russian Society for the Study of Pain “Rational Use of Non-steroidal Anti-Inflammatory Drugs”. Rossijskij Zhurnal Gastrojenterologii, Gepatologii, Koloproktologii. 2017;27(5):69-75 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-5-69-75
29. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857
30. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Argas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl
J Med. 2000;343(21):1520-1528. doi: 10.1056/NEJM 200011233 432103
31. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxiband valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081-1091. doi: 10.1056/NEJMoa050330
32. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080. doi: 10.1056/NEJMoa050405
33. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102. doi: 10.1056/NEJMoa050493
34. Back M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012;33:1928-1933. doi: 10.1093/eurheartj/ ehr421
35. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
doi: 10.1136/bmj.332.7553.1302
36. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL programme: a randomized comparison.
Lancet. 2006;368(9549):1771-1781. doi: 10.1016/S0140-6736(06) 69666-9
37. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1(7):e33. doi: 10.1371/journal.pctr.0010033
38. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. doi: 10.1016/S0140-6736(13)60900-9
39. Hirayama A, Tanahashi N, Daida H, Ishiguro N, Chachin M, Siguoka T. Assessing the Cardiovascular Risk Between Celecoxib and Nonselective Nonsteroidal Antiinflammatory Drugs in Patients With Rheumatoid Arthritis and Osteoarthritis. Circ J. 2014;78(1):194-205.
doi: 10.1253/circj.CJ-12-1573
40. Rahme E, Watson DJ, Kong SX, Toubouti Y, Le Lorier J. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2007;16(5):493-503.
doi: 10.1002/pds.1339
41. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, Torp-Pedersen C, Gislason GH. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235.
doi: 10.1161/CIRCULATIONAHA.110.004671
42. Sudano I, Flammer AJ, Roas S, Enseleit F, Noll G, Ruschitzka F. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep. 2012;14(4):304-309. doi: 10.1007/s11906-012-0274-7
43. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009;104(6):840-845. doi: 10.1016/ j.amjcard.2009.05.014
44. Dallob A, Hawkey CJ, Greenberg HM, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. J Clin Pharmacol. 2003;43(6):573-585. doi: 10.1177/ 0091270003253703
45. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA. 2012;109(43):17597-17602. doi: 10.1073/pnas. 1209192109
46. St Germaine CG, Bogaty P, Boyer L, Hanley J, Engert JC, Brophy JM. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. Am J Cardiol. 2010;105(12):1740-1745.
doi: 10.1016/j.amjcard.2010.01.352
47. Shapiro MS. An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated Puzzle? Mol Pharmacol. 2009;76:942-945. doi: 10.1124/ mol.109.059683
48. Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42:27-38.
doi: 10.1111/jcpt.12484
49. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DPM, Nurmohamed MT. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016;0:1-12. doi: 10.1136/annrheumdis-2016-209775
50. Horbach SJ, Lopes RD, da C Guaragna JC, Martini F, Mehta RH, Petracco JB, Bodanese LC, Filho AC, Cirenza C, de Paola AA. NAFARM Investigators. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med. 2011;124(11):1036-1042. doi: 10.1016/j.amjmed.2011.07.026
51. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68(3):367-372. doi: 10.1136/ ard.2007.076760
52. Lindhardsen J, Gislason GH, Jacobsen S, Ahlehoff O, Olsen AMS, Madsen OR, Torp-Pedersen C, Hansen PR. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;73(8):1515-1521. doi: 10.1136/annrheumdis-2012-203137
53. De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol. 2014;62(6):437-448. PubMed ID 25029569. http://www.minervamedica.it/en/journals/minerva-cardioangiologica/article.php?cod=R05 Y9999N00A 140053
54. MacDonald Т, Hawkey С, Ford I, et al. On behalf of SCOT investigators (The Standard Care versus Celecoxib Outcome Trial). BMJ Open. 2013;3:e002295. https://clinicaltrials.gov/ct2/show/NCT00447759
55. Nissen SE, Yeomans ND, Solomon DH, Luscher TF, et al. for the PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New Engl J Med. 2016.
doi: 10.1056/NEJMoa1611593
56. Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewé R, van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3:e000397. doi: 10.1136/rmdopen-2016-000397
57. Tsai W-C, Ou T-T, Yen J-H, Wu C-C, Tung Y-C. Long-Term Frequent Use of Non-Steroidal Anti-Inflammatory Drugs Might Protect Patients with Ankylosing Spondylitis from Cardiovascular Diseases: A Nationwide Case-Control Study. PLoS ONE. 2015;10(5):e0126347.
doi: 10.1371/journal.pone.0126347
58. Ogdie A, Yu Y, Haynes K, Love TJ, et al. Risk of Major Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A population-based cohort study. Ann Rheum Dis. 2015 Feb;74(2):326-332. doi: 10.1136/annrheumdis-2014-205675
59. Kristensen LE, Jakobsen AK, Askling J, et al. Safety of etoricoxib, celecoxib, and nonselective nonsteroidal antiinflammatory drugs in ankylosing spondylitis and other spondyloarthritis patients: a Swedish National Population-based Cohort Study. Arthritis Care Res (Hoboken). 2015;67:1137-1149. doi: 10.1002 / acr.22555
60. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
61. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-489. doi: 10.1136/annrheumdis-2014-206624
62. Essers I, Stolwijk C, Boonen A, De Bruin ML, Bazelier MT, de Vries F, van Tubergen A. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis. 2016;75:203-209. doi: 10.1136 / annrheumdis-2014-206147
63. Zhang YP, Gong Y, Zeng QY, Hou ZD, Xiao ZY. A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. BMJ Open. 2015;5:e006957. doi: 10.1136/bmjopen-2014-006957
64. Tzu-Chieh Lin, Pharm B, Solomon DH, Tedeschi SK, Yoshida K, Yea-Huei Kao Yang. Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis. Am Heart Assoc. 2017;6:006874.
doi: 10.1161/JAHA.117.006874
2. Каратеев А.Е., Новикова Д.С., Насонов Е.Л. Новые данные, касающиеся безопасности нестероидных противовоспалительных препаратов: представление о «класс-специфическом» высоком кардиоваскулярном риске селективных ингибиторов циклооксигеназы 2 устарело. Научно-практическая ревматология. 2017;55(2):218-223 [Karateev AE, Novikova DS, Nasonov EL. New data on the safety of nonsteroidal anti-inflammatory drugs: the concept of the high class-specific cardiovascular risk of selective cyclooxygenase-2 inhibitors is outdated. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):218-223 (In Russ.)]. doi: 10.14412/ 1995-4484-2017-218-223
3. Peters M, Symmons D, Mccarey D, Dijkmans B, Nicola P, Kvien T, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-331.
doi: 10.1136/ard.2009.113696
4. Peters M, van Halm V, Voskuyl A, Smulders Y, Boers M, Lems W, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A Prospective Study. Arthritis Rheum. 2009;61:1571-1579. doi: 10.1002/art.24836
5. Nicola P, Maradit-Kremers H, Roger V, Jacobsen S, Crowson C, Ballman K, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52:412-420. doi: 10.1002/art.20855
6. Середавкина Н.В., Смирнов А.В., Дыдыкина И.С., Решетняк Т.М. Глюкокортикоиды в лечении системной красной волчанки: положительные и отрицательные стороны. Клиницист. 2014;(1):63-70 [Seredavkina NV, Smirnov AV, Dydykina IS, Reshetnyak TM. Glucocorticoids in the treatment of systemic lupus erythematosus: positive and negative sides. Klinicist. 2014;(1):63-70 (In Russ.)].
doi: 10.17650/1818-8338-2014-1-63-70
7. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337. PMID: 11665973
8. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77-95. doi: 10.1016/ j.semarthrit.2012.12.002
9. Насонов Е.Л., Мазуров В.И., Лила А.М., Эрдес Ш.Ф., Каратеев Д.Е., Верткин А.Л., Зырянов С.К., Дубиков А.И., Фролов М.Ю., Обухова О.В. Резолюция Совещания Экспертов по теме: «Вопросы повышения доступности инновационных методов для пациентов со спондилоартритами». Научно-практическая ревматология. 2017;55(4):457-460 [Nasonov EL, Mazurov VI, Lila AM, Erdes ShF, Karateev DE, Vertkin AL, Zyrjanov SK, Dubikov AI, Frolov MYu, Obuhova OV. Resolution of the Meeting of Experts on the topic: “Issues of increasing the availability of innovative methods for patients with spondylitis”. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):457-460 (In Russ.)].
doi: 10.14412/1995-4484-2017-457-459
10. Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63:550-556.
doi: 10.1002/acr.20408 PMID: 21452267
11. Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294-3304. doi: 10.1002/art.30581
12. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121:S9-S14. doi: 10.1016/j.amjmed.2008. 06.011
13. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010-2019. doi: 10.1002/art.10419
14. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562-2571. PMID: 10606363.
15. Павлова А.Б., Ахвердян Ю.Р., Симакова Е.С. и др. Определение адипонектина у работников промышленных предприятий с воспалительными заболеваниями суставов. Медицина труда и промышленная экология. 2013;(1):38-41 [Pavlova AB, Ahverdjan YuR, Simakova ES, et al. Determination of adiponectin in workers of industrial enterprises with inflammatory diseases of joints. Meditsina Truda i Promyshlennaya Ekologija. 2013;(1):38-41 (In Russ.)].
16. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013;12:1004-1015. doi: 10.1016/j.autrev.2013.03.013
17. Симакова Е.С., Заводовский Б.В., Сивордова Л.Е., Полякова Ю.В., Кравцов В.И., Зборовский А.Б. Прогностическое значение нарушений липидного обмена в патогенезе остеоартроза. Вестник Российской военно-медицинской академии. 2013;2(42):29-32 [Simakova ES, Zavodovskiy BV, Sivordova LE, Poljakova YuV, Kravcov VI, Zborovskiy AB. Prognostic value of violations of lipid metabolism in the pathogenesis of osteoarthritis. Vestnik Rossijskoj Voenno-Medicinskoj Akademii. 2013;2(42):29-32 (In Russ.)].
18. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.
doi: 10.1038/nature10146
19. Stevens R, Douglas K, Saratzis A, Kitas G. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2005;7:1-24. doi: 10.1017/S1462399405009154
20. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51:v3-11. doi: 10.1093/rheumatology/kes113
21. Liao K, Solomon D. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:45-52. doi: 10.3899/jrheum.090188
22. Mavrogeni S, Spargias K, Markussis V, Kolovou G, Demerouti E, Papadopoulou E, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm Allergy Drug Targets. 2009;8:390-397. PMID: 20025587.
23. Sandoo A, Kitas G, Carroll D, Veldhuijzen Van Zanten J. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res Ther. 2012;14:R117. doi: 10.1186/ar3847
24. Драпкина О.М., Ашихмин Я.И. Воздействие нестероидных противовоспалительных средств и селективных ингибиторов циклооксигеназы-2 на сердечно-сосудистую систему. Российские медицинские вести. 2007;12(3):62-66 [Drapkina OM, Ashikhmin YaI. Effect of nonsteroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors on cardio-vascular system. Rossijskie Medicinskie Vesti. 2007;12(3):62-66 (In Russ.)].
25. Сивордова Л.Е., Заводовский Б.В., Полякова Ю.В., Ахвердян Ю.Р. Доказательства целесообразности применения эторикоксиба в терапии остеоартроза у пациентов старших возрастных групп. Успехи геронтологии. 2016;29(2):286-290 [Sivordova LE, Zavodovskij BV, Poljakova YuV, Ahverdyan YuR. Evidence of the feasibility of using etorikoksib in the therapy of osteoarthritis in patients of older age groups. Uspekhi Gerontologii = Advanced Gerontology. 2016;29(2):286-290 (In Russ.)].
26. Насонов Е.Л., Насонова В.А., редакторы. Ревматология: национальное руководство. Москва: ГЭОТАР-Медиа; 2008. 720 с. [Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional’noe rukovodstvo [Rheumatology: National Guidelance]. Moscow: GEOTAR-Media; 2008. 720 p. (In Russ.)].
27. Заводовский Б.В., Сивордова Л.Е., Полякова Ю.В., Ахвердян Ю.Р., Кузнецова М.И., Зборовская И.А. Сравнительная эффективность и безопасность эторикоксиба и мелоксикама в лечении больных гонартрозом. Терапевтический архив. 2016;88:78-81 [Zavodovskij BV, Sivordova LE, Poljakova YuV, Ahverdjan YuR, Kuznecova MI, Zborovskaja IA. Comparative efficacy and safety of etorikoksib and meloxicam in the treatment of patients with gonarthrosis. Terapevticheskij Arhiv. 2016;88:78-81 (In Russ.)]. doi: 10.17116/terarkh 2016881278-81
28. Насонов Е.Л., Ивашкин В.Т., Яхно Н.Н., Мартынов А.И., Арутю-
нов Г.П., Каратеев А.Е., Алексеева Л.И., Чичасова Н.В., Евсеев М.А., Кукушкин М.Л., Лила А.М., Ребров А.П. и др. Проект Национальных клинических рекомендаций (Основные положения) Ассоциации ревматологов России, Российской гастроэнтерологической Ассоциации, Российского общества по изучению боли «Рациональное использование нестероидных противовоспалительных препаратов». Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):69-75 [Nasonov EL, Ivashkin VT, Jahno NN, Martynov AI, Arutjunov GP, Karateev AE, Alekseeva LI, Chichasova NV, Evseev MA, Kukushkin ML, Lila AM, Rebrov AP, et al. Project of National Clinical Recommendations (Basic Provisions) of the Association of Rheumatologists of Russia, the Russian Gastroenterological Association, the Russian Society for the Study of Pain “Rational Use of Non-steroidal Anti-Inflammatory Drugs”. Rossijskij Zhurnal Gastrojenterologii, Gepatologii, Koloproktologii. 2017;27(5):69-75 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-5-69-75
29. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857
30. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Argas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl
J Med. 2000;343(21):1520-1528. doi: 10.1056/NEJM 200011233 432103
31. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxiband valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081-1091. doi: 10.1056/NEJMoa050330
32. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080. doi: 10.1056/NEJMoa050405
33. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102. doi: 10.1056/NEJMoa050493
34. Back M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012;33:1928-1933. doi: 10.1093/eurheartj/ ehr421
35. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
doi: 10.1136/bmj.332.7553.1302
36. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL programme: a randomized comparison.
Lancet. 2006;368(9549):1771-1781. doi: 10.1016/S0140-6736(06) 69666-9
37. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1(7):e33. doi: 10.1371/journal.pctr.0010033
38. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. doi: 10.1016/S0140-6736(13)60900-9
39. Hirayama A, Tanahashi N, Daida H, Ishiguro N, Chachin M, Siguoka T. Assessing the Cardiovascular Risk Between Celecoxib and Nonselective Nonsteroidal Antiinflammatory Drugs in Patients With Rheumatoid Arthritis and Osteoarthritis. Circ J. 2014;78(1):194-205.
doi: 10.1253/circj.CJ-12-1573
40. Rahme E, Watson DJ, Kong SX, Toubouti Y, Le Lorier J. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2007;16(5):493-503.
doi: 10.1002/pds.1339
41. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, Torp-Pedersen C, Gislason GH. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235.
doi: 10.1161/CIRCULATIONAHA.110.004671
42. Sudano I, Flammer AJ, Roas S, Enseleit F, Noll G, Ruschitzka F. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep. 2012;14(4):304-309. doi: 10.1007/s11906-012-0274-7
43. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009;104(6):840-845. doi: 10.1016/ j.amjcard.2009.05.014
44. Dallob A, Hawkey CJ, Greenberg HM, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. J Clin Pharmacol. 2003;43(6):573-585. doi: 10.1177/ 0091270003253703
45. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA. 2012;109(43):17597-17602. doi: 10.1073/pnas. 1209192109
46. St Germaine CG, Bogaty P, Boyer L, Hanley J, Engert JC, Brophy JM. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. Am J Cardiol. 2010;105(12):1740-1745.
doi: 10.1016/j.amjcard.2010.01.352
47. Shapiro MS. An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated Puzzle? Mol Pharmacol. 2009;76:942-945. doi: 10.1124/ mol.109.059683
48. Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42:27-38.
doi: 10.1111/jcpt.12484
49. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DPM, Nurmohamed MT. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016;0:1-12. doi: 10.1136/annrheumdis-2016-209775
50. Horbach SJ, Lopes RD, da C Guaragna JC, Martini F, Mehta RH, Petracco JB, Bodanese LC, Filho AC, Cirenza C, de Paola AA. NAFARM Investigators. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med. 2011;124(11):1036-1042. doi: 10.1016/j.amjmed.2011.07.026
51. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68(3):367-372. doi: 10.1136/ ard.2007.076760
52. Lindhardsen J, Gislason GH, Jacobsen S, Ahlehoff O, Olsen AMS, Madsen OR, Torp-Pedersen C, Hansen PR. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;73(8):1515-1521. doi: 10.1136/annrheumdis-2012-203137
53. De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol. 2014;62(6):437-448. PubMed ID 25029569. http://www.minervamedica.it/en/journals/minerva-cardioangiologica/article.php?cod=R05 Y9999N00A 140053
54. MacDonald Т, Hawkey С, Ford I, et al. On behalf of SCOT investigators (The Standard Care versus Celecoxib Outcome Trial). BMJ Open. 2013;3:e002295. https://clinicaltrials.gov/ct2/show/NCT00447759
55. Nissen SE, Yeomans ND, Solomon DH, Luscher TF, et al. for the PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New Engl J Med. 2016.
doi: 10.1056/NEJMoa1611593
56. Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewé R, van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3:e000397. doi: 10.1136/rmdopen-2016-000397
57. Tsai W-C, Ou T-T, Yen J-H, Wu C-C, Tung Y-C. Long-Term Frequent Use of Non-Steroidal Anti-Inflammatory Drugs Might Protect Patients with Ankylosing Spondylitis from Cardiovascular Diseases: A Nationwide Case-Control Study. PLoS ONE. 2015;10(5):e0126347.
doi: 10.1371/journal.pone.0126347
58. Ogdie A, Yu Y, Haynes K, Love TJ, et al. Risk of Major Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A population-based cohort study. Ann Rheum Dis. 2015 Feb;74(2):326-332. doi: 10.1136/annrheumdis-2014-205675
59. Kristensen LE, Jakobsen AK, Askling J, et al. Safety of etoricoxib, celecoxib, and nonselective nonsteroidal antiinflammatory drugs in ankylosing spondylitis and other spondyloarthritis patients: a Swedish National Population-based Cohort Study. Arthritis Care Res (Hoboken). 2015;67:1137-1149. doi: 10.1002 / acr.22555
60. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
61. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-489. doi: 10.1136/annrheumdis-2014-206624
62. Essers I, Stolwijk C, Boonen A, De Bruin ML, Bazelier MT, de Vries F, van Tubergen A. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis. 2016;75:203-209. doi: 10.1136 / annrheumdis-2014-206147
63. Zhang YP, Gong Y, Zeng QY, Hou ZD, Xiao ZY. A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. BMJ Open. 2015;5:e006957. doi: 10.1136/bmjopen-2014-006957
64. Tzu-Chieh Lin, Pharm B, Solomon DH, Tedeschi SK, Yoshida K, Yea-Huei Kao Yang. Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis. Am Heart Assoc. 2017;6:006874.
doi: 10.1161/JAHA.117.006874
________________________________________________
2. Karateev AE, Novikova DS, Nasonov EL. New data on the safety of nonsteroidal anti-inflammatory drugs: the concept of the high class-specific cardiovascular risk of selective cyclooxygenase-2 inhibitors is outdated. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):218-223 (In Russ.)]. doi: 10.14412/ 1995-4484-2017-218-223
3. Peters M, Symmons D, Mccarey D, Dijkmans B, Nicola P, Kvien T, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-331.
doi: 10.1136/ard.2009.113696
4. Peters M, van Halm V, Voskuyl A, Smulders Y, Boers M, Lems W, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A Prospective Study. Arthritis Rheum. 2009;61:1571-1579. doi: 10.1002/art.24836
5. Nicola P, Maradit-Kremers H, Roger V, Jacobsen S, Crowson C, Ballman K, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52:412-420. doi: 10.1002/art.20855
6. [Seredavkina NV, Smirnov AV, Dydykina IS, Reshetnyak TM. Glucocorticoids in the treatment of systemic lupus erythematosus: positive and negative sides. Klinicist. 2014;(1):63-70 (In Russ.)].
doi: 10.17650/1818-8338-2014-1-63-70
7. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337. PMID: 11665973
8. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77-95. doi: 10.1016/ j.semarthrit.2012.12.002
9. [Nasonov EL, Mazurov VI, Lila AM, Erdes ShF, Karateev DE, Vertkin AL, Zyrjanov SK, Dubikov AI, Frolov MYu, Obuhova OV. Resolution of the Meeting of Experts on the topic: “Issues of increasing the availability of innovative methods for patients with spondylitis”. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):457-460 (In Russ.)].
doi: 10.14412/1995-4484-2017-457-459
10. Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63:550-556.
doi: 10.1002/acr.20408 PMID: 21452267
11. Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294-3304. doi: 10.1002/art.30581
12. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121:S9-S14. doi: 10.1016/j.amjmed.2008. 06.011
13. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010-2019. doi: 10.1002/art.10419
14. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562-2571. PMID: 10606363.
15. [Pavlova AB, Ahverdjan YuR, Simakova ES, et al. Determination of adiponectin in workers of industrial enterprises with inflammatory diseases of joints. Meditsina Truda i Promyshlennaya Ekologija. 2013;(1):38-41 (In Russ.)].
16. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013;12:1004-1015. doi: 10.1016/j.autrev.2013.03.013
17. [Simakova ES, Zavodovskiy BV, Sivordova LE, Poljakova YuV, Kravcov VI, Zborovskiy AB. Prognostic value of violations of lipid metabolism in the pathogenesis of osteoarthritis. Vestnik Rossijskoj Voenno-Medicinskoj Akademii. 2013;2(42):29-32 (In Russ.)].
18. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.
doi: 10.1038/nature10146
19. Stevens R, Douglas K, Saratzis A, Kitas G. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2005;7:1-24. doi: 10.1017/S1462399405009154
20. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51:v3-11. doi: 10.1093/rheumatology/kes113
21. Liao K, Solomon D. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:45-52. doi: 10.3899/jrheum.090188
22. Mavrogeni S, Spargias K, Markussis V, Kolovou G, Demerouti E, Papadopoulou E, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm Allergy Drug Targets. 2009;8:390-397. PMID: 20025587.
23. Sandoo A, Kitas G, Carroll D, Veldhuijzen Van Zanten J. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res Ther. 2012;14:R117. doi: 10.1186/ar3847
24. [Drapkina OM, Ashikhmin YaI. Effect of nonsteroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors on cardio-vascular system. Rossijskie Medicinskie Vesti. 2007;12(3):62-66 (In Russ.)].
25. [Sivordova LE, Zavodovskij BV, Poljakova YuV, Ahverdyan YuR. Evidence of the feasibility of using etorikoksib in the therapy of osteoarthritis in patients of older age groups. Uspekhi Gerontologii = Advanced Gerontology. 2016;29(2):286-290 (In Russ.)].
26. [Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional’noe rukovodstvo [Rheumatology: National Guidelance]. Moscow: GEOTAR-Media; 2008. 720 p. (In Russ.)].
27. [Zavodovskij BV, Sivordova LE, Poljakova YuV, Ahverdjan YuR, Kuznecova MI, Zborovskaja IA. Comparative efficacy and safety of etorikoksib and meloxicam in the treatment of patients with gonarthrosis. Terapevticheskij Arhiv. 2016;88:78-81 (In Russ.)]. doi: 10.17116/terarkh 2016881278-81
28. [Nasonov EL, Ivashkin VT, Jahno NN, Martynov AI, Arutjunov GP, Karateev AE, Alekseeva LI, Chichasova NV, Evseev MA, Kukushkin ML, Lila AM, Rebrov AP, et al. Project of National Clinical Recommendations (Basic Provisions) of the Association of Rheumatologists of Russia, the Russian Gastroenterological Association, the Russian Society for the Study of Pain “Rational Use of Non-steroidal Anti-Inflammatory Drugs”. Rossijskij Zhurnal Gastrojenterologii, Gepatologii, Koloproktologii. 2017;27(5):69-75 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-5-69-75
29. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857
30. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Argas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl
J Med. 2000;343(21):1520-1528. doi: 10.1056/NEJM 200011233 432103
31. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxiband valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081-1091. doi: 10.1056/NEJMoa050330
32. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080. doi: 10.1056/NEJMoa050405
33. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102. doi: 10.1056/NEJMoa050493
34. Back M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012;33:1928-1933. doi: 10.1093/eurheartj/ ehr421
35. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
doi: 10.1136/bmj.332.7553.1302
36. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL programme: a randomized comparison.
Lancet. 2006;368(9549):1771-1781. doi: 10.1016/S0140-6736(06) 69666-9
37. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1(7):e33. doi: 10.1371/journal.pctr.0010033
38. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. doi: 10.1016/S0140-6736(13)60900-9
39. Hirayama A, Tanahashi N, Daida H, Ishiguro N, Chachin M, Siguoka T. Assessing the Cardiovascular Risk Between Celecoxib and Nonselective Nonsteroidal Antiinflammatory Drugs in Patients With Rheumatoid Arthritis and Osteoarthritis. Circ J. 2014;78(1):194-205.
doi: 10.1253/circj.CJ-12-1573
40. Rahme E, Watson DJ, Kong SX, Toubouti Y, Le Lorier J. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2007;16(5):493-503.
doi: 10.1002/pds.1339
41. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, Torp-Pedersen C, Gislason GH. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235.
doi: 10.1161/CIRCULATIONAHA.110.004671
42. Sudano I, Flammer AJ, Roas S, Enseleit F, Noll G, Ruschitzka F. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep. 2012;14(4):304-309. doi: 10.1007/s11906-012-0274-7
43. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009;104(6):840-845. doi: 10.1016/ j.amjcard.2009.05.014
44. Dallob A, Hawkey CJ, Greenberg HM, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. J Clin Pharmacol. 2003;43(6):573-585. doi: 10.1177/ 0091270003253703
45. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA. 2012;109(43):17597-17602. doi: 10.1073/pnas. 1209192109
46. St Germaine CG, Bogaty P, Boyer L, Hanley J, Engert JC, Brophy JM. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. Am J Cardiol. 2010;105(12):1740-1745.
doi: 10.1016/j.amjcard.2010.01.352
47. Shapiro MS. An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated Puzzle? Mol Pharmacol. 2009;76:942-945. doi: 10.1124/ mol.109.059683
48. Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42:27-38.
doi: 10.1111/jcpt.12484
49. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DPM, Nurmohamed MT. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016;0:1-12. doi: 10.1136/annrheumdis-2016-209775
50. Horbach SJ, Lopes RD, da C Guaragna JC, Martini F, Mehta RH, Petracco JB, Bodanese LC, Filho AC, Cirenza C, de Paola AA. NAFARM Investigators. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med. 2011;124(11):1036-1042. doi: 10.1016/j.amjmed.2011.07.026
51. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68(3):367-372. doi: 10.1136/ ard.2007.076760
52. Lindhardsen J, Gislason GH, Jacobsen S, Ahlehoff O, Olsen AMS, Madsen OR, Torp-Pedersen C, Hansen PR. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;73(8):1515-1521. doi: 10.1136/annrheumdis-2012-203137
53. De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol. 2014;62(6):437-448. PubMed ID 25029569. http://www.minervamedica.it/en/journals/minerva-cardioangiologica/article.php?cod=R05 Y9999N00A 140053
54. MacDonald Т, Hawkey С, Ford I, et al. On behalf of SCOT investigators (The Standard Care versus Celecoxib Outcome Trial). BMJ Open. 2013;3:e002295. https://clinicaltrials.gov/ct2/show/NCT00447759
55. Nissen SE, Yeomans ND, Solomon DH, Luscher TF, et al. for the PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New Engl J Med. 2016.
doi: 10.1056/NEJMoa1611593
56. Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewé R, van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3:e000397. doi: 10.1136/rmdopen-2016-000397
57. Tsai W-C, Ou T-T, Yen J-H, Wu C-C, Tung Y-C. Long-Term Frequent Use of Non-Steroidal Anti-Inflammatory Drugs Might Protect Patients with Ankylosing Spondylitis from Cardiovascular Diseases: A Nationwide Case-Control Study. PLoS ONE. 2015;10(5):e0126347.
doi: 10.1371/journal.pone.0126347
58. Ogdie A, Yu Y, Haynes K, Love TJ, et al. Risk of Major Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A population-based cohort study. Ann Rheum Dis. 2015 Feb;74(2):326-332. doi: 10.1136/annrheumdis-2014-205675
59. Kristensen LE, Jakobsen AK, Askling J, et al. Safety of etoricoxib, celecoxib, and nonselective nonsteroidal antiinflammatory drugs in ankylosing spondylitis and other spondyloarthritis patients: a Swedish National Population-based Cohort Study. Arthritis Care Res (Hoboken). 2015;67:1137-1149. doi: 10.1002 / acr.22555
60. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
61. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-489. doi: 10.1136/annrheumdis-2014-206624
62. Essers I, Stolwijk C, Boonen A, De Bruin ML, Bazelier MT, de Vries F, van Tubergen A. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis. 2016;75:203-209. doi: 10.1136 / annrheumdis-2014-206147
63. Zhang YP, Gong Y, Zeng QY, Hou ZD, Xiao ZY. A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. BMJ Open. 2015;5:e006957. doi: 10.1136/bmjopen-2014-006957
64. Tzu-Chieh Lin, Pharm B, Solomon DH, Tedeschi SK, Yoshida K, Yea-Huei Kao Yang. Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis. Am Heart Assoc. 2017;6:006874.
doi: 10.1161/JAHA.117.006874
Авторы
Б.В. Заводовский, Л.Е. Сивордова
ФГБНУ «Научно-исследовательский институт клинической и экспериментальной ревматологии им. А.Б. Зборовского», Волгоград,
Россия
A.B. Zborovsky Research Institute of Clinical and Experimental Rheumatology, Volgograd, Russia
ФГБНУ «Научно-исследовательский институт клинической и экспериментальной ревматологии им. А.Б. Зборовского», Волгоград,
Россия
________________________________________________
A.B. Zborovsky Research Institute of Clinical and Experimental Rheumatology, Volgograd, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.